Brainstorm Cell Therapeutics (BCLI) investor relations material

Company overview and business model

• Focuses on developing and commercializing autologous cellular therapies for neurodegenerative diseases, including ALS, PMS, and AD, using its proprietary NurOwn® platform.

• NurOwn® leverages bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammation, and promote neuronal survival.

• Holds exclusive global commercialization rights to NurOwn® through a licensing agreement with Ramot at Tel Aviv University.

• Employs 20 staff across the US and Israel, with R&D based in Israel and clinical operations in the US.

Financial performance and metrics

• No operational revenues since inception; continues to incur substantial operating losses.

• Net loss for 2025 was $10.3 million, down from $11.6 million in 2024; net loss for Q1 2026 was $2.1 million.

• Research and development expenses for 2025 were $4.2 million, a decrease from $4.7 million in 2024.

• Cash, cash equivalents, and restricted cash totaled $206,000 as of March 31, 2026.

• Additional funding required for commercialization and ongoing operations; recent private placements and loans raised limited capital.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of offered securities by selling securityholders, except for warrant exercise proceeds.

• Proceeds from warrant exercises will be used for working capital purposes.

• Ongoing capital needs include funding clinical trials, regulatory activities, and commercialization efforts.